76 related articles for article (PubMed ID: 32541460)
61. Overcoming endocrine resistance in hormone receptor-positive breast cancer.
AlFakeeh A; Brezden-Masley C
Curr Oncol; 2018 Jun; 25(Suppl 1):S18-S27. PubMed ID: 29910644
[TBL] [Abstract][Full Text] [Related]
62. A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast Cancer.
Mahtani R; Holmes FA; Badve S; Caldera H; Coleman R; Mamounas E; Kalinsky K; Kittaneh M; Lower E; Pegram M; Press MF; Rugo HS; Schwartzberg L; Vogel C;
Clin Breast Cancer; 2020 Jun; 20(3):e251-e260. PubMed ID: 32139271
[TBL] [Abstract][Full Text] [Related]
63. Real-world Data on First-line Systemic Therapy for Hormone Receptor-positive HER2-negative Metastatic Breast Cancer: A Trend Shift in the Era of CDK 4/6 Inhibitors.
Werutsky G; Reinert T; Rosa ML; Barrios CH
Clin Breast Cancer; 2021 Dec; 21(6):e688-e692. PubMed ID: 33992526
[TBL] [Abstract][Full Text] [Related]
64. Optimizing the treatment of metastatic breast cancer.
Gralow JR
Breast Cancer Res Treat; 2005; 89 Suppl 1():S9-S15. PubMed ID: 15770536
[TBL] [Abstract][Full Text] [Related]
65. Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.
Carlson RW; Henderson IC
Breast Cancer Res Treat; 2003; 80 Suppl 1():S19-26; discussion S27-8. PubMed ID: 14535531
[TBL] [Abstract][Full Text] [Related]
66. Issues concerning the role of chemotherapy and hormonal therapy of bone metastases from breast carcinoma.
Harvey HA
Cancer; 1997 Oct; 80(8 Suppl):1646-51. PubMed ID: 9362431
[TBL] [Abstract][Full Text] [Related]
67. Ribociclib in HR+/HER2- Advanced or Metastatic Breast Cancer Patients.
Rascon K; Flajc G; De Angelis C; Liu X; Trivedi MV; Ekinci E
Ann Pharmacother; 2019 May; 53(5):501-509. PubMed ID: 30522347
[TBL] [Abstract][Full Text] [Related]
68. Navigating the Challenges of Endocrine Treatments in Premenopausal Women with ER-Positive Early Breast Cancer.
Colleoni M; Munzone E
Drugs; 2015 Aug; 75(12):1311-21. PubMed ID: 26177891
[TBL] [Abstract][Full Text] [Related]
69. Maintenance hormonal and chemotherapy treatment in metastatic breast cancer: a systematic review.
Rossi S; Schinzari G; Basso M; Strippoli A; Dadduzio V; D'Argento E; Cassano A; Barone C
Future Oncol; 2016 May; 12(10):1299-307. PubMed ID: 26996100
[TBL] [Abstract][Full Text] [Related]
70. Estrogen, progesterone, and HER2/neu receptor discordance between primary and metastatic breast tumours-a review.
Yeung C; Hilton J; Clemons M; Mazzarello S; Hutton B; Haggar F; Addison CL; Kuchuk I; Zhu X; Gelmon K; Arnaout A
Cancer Metastasis Rev; 2016 Sep; 35(3):427-37. PubMed ID: 27405651
[TBL] [Abstract][Full Text] [Related]
71. A Representative Clinical Course of Progression, with Molecular Insights, of Hormone Receptor-Positive, HER2-Negative Bone Metastatic Breast Cancer.
Magno E; Bussard KM
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542380
[TBL] [Abstract][Full Text] [Related]
72. Impressive long-term response with chemo-endocrine therapy in a premenopausal patient with metastatic breast cancer: A case report.
Maltoni R; Palleschi M; Gallerani G; Bravaccini S; Cecconetto L; Melegari E; Altini M; Rocca A
Medicine (Baltimore); 2020 Jun; 99(24):e20396. PubMed ID: 32541460
[TBL] [Abstract][Full Text] [Related]
73. The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2.
Prat A; Baselga J
Nat Clin Pract Oncol; 2008 Sep; 5(9):531-42. PubMed ID: 18607391
[TBL] [Abstract][Full Text] [Related]
74. Trastuzumab-containing regimens for metastatic breast cancer.
Balduzzi S; Mantarro S; Guarneri V; Tagliabue L; Pistotti V; Moja L; D'Amico R
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD006242. PubMed ID: 24919460
[TBL] [Abstract][Full Text] [Related]
75. The curability of breast cancer and the treatment of advanced disease.
Guarneri V; Conte PF
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S149-61. PubMed ID: 15107948
[TBL] [Abstract][Full Text] [Related]
76. A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.
Jerusalem G; Bachelot T; Barrios C; Neven P; Di Leo A; Janni W; de Boer R
Cancer Treat Rev; 2015 Feb; 41(2):94-104. PubMed ID: 25575443
[TBL] [Abstract][Full Text] [Related]
[Previous] [New Search]